Login to Your Account

Vernalis Emerges from Rough Patch with Royalty Stream, Cash

By Jennifer Boggs

Tuesday, February 16, 2010
Vernalis plc is raising £30 million (US$47 million) in a stock sale to buy back its royalty stream for migraine drug frovatriptan and shore up its bank balance ahead of much-awaited data from its Phase IIb trial of V3381 in neuropathic pain. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription